One stock that hasn't benefitted from the S&P's 2013 climb is Amgen (AMGN), the $64 billion pharmaceutical stock. Instead, Amgen has mostly churned sideways this year. But that could be about to change thanks to a bullish setup that's been forming in shares.
Amgen is currently forming an ascending triangle pattern, a technical setup that's formed by a horizontal resistance level to the upside and uptrending support sitting right below shares. Essentially, as AMGN bounces in between those two technical price levels, it's getting squeezed closer and closer to a breakout above resistance at $90. When the breakout happens, we've got a buy signal for this stock.Pharmaceutical names have been acting "funny" for the last few months, stumbling only to make a move higher. That's good enough reason to keep a tight stop on AMGN. The 200-day moving average is becoming a pretty good proxy for support right now, so it's a reasonable place to put your stop.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV